KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Equity Average: 2009-2024

Historic Equity Average for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $6.8 billion.

  • Teva Pharmaceutical Industries' Equity Average rose 8.82% to $7.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 billion, marking a year-over-year increase of 8.82%. This contributed to the annual value of $6.8 billion for FY2024, which is 19.24% down from last year.
  • Teva Pharmaceutical Industries' Equity Average amounted to $6.8 billion in FY2024, which was down 19.24% from $8.4 billion recorded in FY2023.
  • In the past 5 years, Teva Pharmaceutical Industries' Equity Average ranged from a high of $13.1 billion in FY2020 and a low of $6.8 billion during FY2024.
  • For the 3-year period, Teva Pharmaceutical Industries' Equity Average averaged around $8.3 billion, with its median value being $8.4 billion (2023).
  • Data for Teva Pharmaceutical Industries' Equity Average shows a maximum YoY dropped of 19.24% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Teva Pharmaceutical Industries' Equity Average stood at $13.1 billion in 2020, then decreased by 14.62% to $11.2 billion in 2021, then declined by 11.04% to $9.9 billion in 2022, then dropped by 15.71% to $8.4 billion in 2023, then decreased by 19.24% to $6.8 billion in 2024.